An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …

Efficient therapeutic options are needed to control the spread of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 …

SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging
vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-…

VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike
glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 …

Productive infection by herpesviruses involve the disabling of host-cell intrinsic defenses by
viral encoded tegument proteins. Epstein-Barr Virus (EBV) typically establishes a non-…

SARS-CoV-2 can mutate to evade immunity, with consequences for the efficacy of emerging
vaccines and antibody therapeutics. Herein we demonstrate that the immunodominant …

Nonhuman primates are widely used to study correlates of protective immunity in AIDS
research. Successful cellular immune responses have been difficult to identify because …

Sexual transmission of human immunodeficiency virus type 1 (HIV-1) across mucosal
barriers is responsible for the vast majority of new infections. This relatively inefficient process …

Human Immunodeficiency Virus (HIV) relies on host molecular machinery for replication.
Systematic attempts to genetically or biochemically define these host factors have yielded …

Rift Valley fever virus (RVFV) causes recurrent insect-borne epizootics throughout the African
continent, and infection of humans can lead to a lethal hemorrhagic fever syndrome. Deep …